Glaucoma is often controlled, but never cured by daily use of eye drops. Some forms of glaucoma are not treated by current glaucoma drugs, and glaucoma is the second most prevalent cause of blindness in the USA. Rho kinase inhibitors are a new class of glaucoma drugs that offer significant improvement over existing treatment options. BioAxone is developing a “better-than-class” novel ROCK2-selective  inhibitor for treatment of glaucoma.